Medical Guidelines For Fop Published In Jbmrplus Ifopa

Leo Migdal

-Dec 5, 2025, 5:23 PM

medical guidelines for fop published in jbmrplus ifopa

Medical Guidelines for FOP Published in JBMRPlus We’re pleased to share that the International Clinical Council (ICC) on FOP has published the Medical Guidelines for FOP in JBMRPlus, a publication of the American Society... This publication represents an important milestone in improving global access to accurate, peer-reviewed information on FOP care — ensuring that clinicians, researchers, and regulatory agencies can find and reference the Treatment Guidelines more easily. As Corresponding Editors Drs. Fred Kaplan and Bob Pignolo note, this published summary streamlines and supplements the main document but does not replace it. We encourage healthcare professionals and partners to download, print, and share this 13-page resource with their teams to help improve patient care. Learn more and access the Medical Guidelines: https://lnkd.in/dCvA-pz9 #FOPawareness #HealthcareProfessionals #RareBoneDisease #PatientCare

The Brain & Performance Centre Becomes the First UHMS-Accredited Hyperbaric Medicine Facility in the Middle East Accreditation underscores the Centre’s global leadership in hyperbaric medicine, patient safety, and scientific excellence. The Brain & Performance Centre, a DP World company, has officially received accreditation from the Undersea and Hyperbaric Medical Society (UHMS) — the world’s foremost authority on hyperbaric medicine. #Middle_East https://lnkd.in/d-GnzcTm 𝗡𝗲𝘄 𝗘𝘃𝗶𝗱𝗲𝗻𝗰𝗲 𝗙𝗿𝗼𝗺 𝗧𝗲𝘅𝗮𝘀! We are pleased to spotlight a new publication, 𝘊𝘶𝘮𝘶𝘭𝘢𝘵𝘪𝘷𝘦 𝘉𝘶𝘳𝘥𝘦𝘯 𝘰𝘧 𝘕𝘰𝘯-𝘔𝘦𝘥𝘪𝘤𝘢𝘭 𝘋𝘳𝘪𝘷𝘦𝘳𝘴 𝘰𝘧 𝘏𝘦𝘢𝘭𝘵𝘩 𝘢𝘯𝘥 𝘛𝘩𝘦𝘪𝘳 𝘈𝘴𝘴𝘰𝘤𝘪𝘢𝘵𝘪𝘰𝘯𝘴 𝘸𝘪𝘵𝘩 𝘏𝘰𝘴𝘱𝘪𝘵𝘢𝘭 𝘜𝘵𝘪𝘭𝘪𝘻𝘢𝘵𝘪𝘰𝘯 in The American Journal of Medical Sciences. This study was based on data from a Medical-Legal Partnership (MLP) embedded within a primary care clinic in Houston.

Researchers examined adverse non-medical drivers of health, including issues with housing, hunger, transportation, employment, safety, and more. In this setting, about 1 in 7 patients reported having four or more NMDOH concerns. The study found that NMDOH has a cumulative effect on higher cost healthcare utilization. 📈 Those with four or more adverse NMDOH were more likely to have multiple emergency department visits and hospital stays lasting two or more days. MLPs may serve as one approach for addressing the multiple, overlapping NMDOH to improve health and reduce higher-cost healthcare utilization. Read the report here: https://lnkd.in/gSkkShXx If you have an MLP, there is still time to submit a proposal to share your story at the 2026 Medical-Legal Partnership Conference, April 16 - 18, 2026, in...

The submission deadline is October 31, 2025, at: https://lnkd.in/eA4-RsHN AASLD #TLM25 has officially begun! Our experts Dr Marlyn Mayo and Dr Andreas Kremer, highlight the sessions and breakthroughs in PBC and PSC that they’re tracking closely at the congress, in this short video: https://lnkd.in/eT2x6_wF --- This program is... This educational content is not intended for healthcare professionals in the UK or US. #AASLD25 #hepatology #medicaleducation #IME #SpringerHealthPlus 📢 New Section on the DMP Website We are excited to announce the launch of a new “Guidelines, Consensus Statements, Clinical & Research Tools” tab on our website.

This section features key materials published in Dental and Medical Problems (DMP) — including guidelines, consensus statements, validated questionnaires, and expert recommendations. All resources are published in open access, ensuring they are freely available to researchers, clinicians, and healthcare professionals worldwide. 🔗 Visit the section and stay up to date with new, evidence-based tools: https://lnkd.in/dZH8jKtv #Diabetes #DMP #Guidelines #Consensus #ResearchTools #OpenAccess #MedicalResearch Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare genetic condition characterized by congenital malformations of the great toes and progressive heterotopic ossification (HO) in specific anatomic patterns. Present management summarized here is focused on early diagnosis, assiduous avoidance of injury and iatrogenic harm, symptomatic amelioration of painful flare-ups, and optimization of residual function. Twenty-one members of the International Clinical Council on FOP (ICC) and seven consultants from 15 countries, chosen for their clinical expertise in FOP, developed this summary statement.

Further advances in therapeutics will be based on rigorous clinical trials to assess novel and emerging treatment and prevention strategies. A detailed and updated exploration of the topics outlined in this brief perspective can be found in "The Medical Management of Fibrodysplasia Ossificans Progressiva: Current Treatment Considerations" which can be found on the International... Keywords: ACVR1; BMP signaling pathway; fibrodysplasia ossificans progressiva; guidelines; heterotopic ossification. © The Author(s) 2025. Published by Oxford University Press on behalf of the American Society for Bone and Mineral Research. F.S.K.

is a clinical trial investigator for Ashibio, Incyte, Ipsen, and Regeneron and serves in an unpaid capacity on the Medical Registry Advisory Board of the International Fibrodysplasia Ossificans Progressiva Association, the International Clinical Council... M.A.M. is a clinical trial investigator for Ashibio, Incyte, Ipsen, and Regeneron, and serves in an unpaid capacity on the Medical Registry Advisory Board of the International Fibrodysplasia Ossificans Progressiva Association, the International Clinical Council... G.B. has research grants and conference support from FOP France and Ipsen, is a clinical trial investigator for Incyte, Ipsen, and Regeneron, is a member of the Medical Registry Advisory Board of the IFOPA, of... A.H.B.

is a clinical trial investigator for Incyte, Ipsen, and Regeneron. M.B. is a clinical trial investigator for Incyte, Ipsen, and Regeneron. A.C. is a trustee of The Radiant Hope Foundation. T-J.C.

is a clinical trial investigator for Incyte and Ipsen. C.C.: None declared. C.L.D.C. is a clinical trial investigator for Incyte and Ipsen and a member of the Medical Registry Advisory Board of the IFOPA. P.D. is a consultant for Ipsen, a clinical trial investigator for Incyte, Ipsen, and Regeneron, and a member of the Board of Directors of Tin Soldiers Global and the Noi Ci Siamo Association in Switzerland.

R.J.D.: None declared. E.M.W.E. is a clinical trial investigator for STOPFOP, Regeneron, Ipsen, and Incyte, a member of the Medical Registry Advisory Board of the IFOPA, the steering committee of the Amsterdam Bone Center, the European Reference Network... L.F.: None declared. C.F. is a consultant for Ipsen, Clinical Director for The Special Olympics, a member of the Board of Directors of Tin Soldiers Global, and has received an honorarium from Springer for a presentation.

Z.G. is a consultant for the Axdev Group. N.H. was a clinical investigator for Ipsen. E.C.H. serves in an unpaid capacity on the Medical Registry Advisory Board of the International Fibrodysplasia Ossificans Progressiva Association; the Fibrous Dysplasia Foundation Medical and Scientific Advisory Boards; and the International Clinical Council on FOP.

ECH receives support for clinical trials through his institution from Clementia Pharmaceuticals, an Ipsen Company; Ipsen Pharmaceuticals; Ascendis; and āshibio. R.K. is a consultant for Ipsen, Alexion, Kyowa Kirin, UCB, Amgen, and Richter, a member of the Advisory Board of Alexion, Kyowa Kirin, Theramex, a clinical investigator for Alexion, Kyowa Kirin, Incyte, Ipsen, and Regeneron,... J.K.: None declared. C.E.L.: None declared. V.M.: None declared.

R.M. is a consultant for Ipsen. J.C.N.: None declared. C.S. is a consultant for Ipsen and was a previous clinical trial investigator for Ipsen and Regeneron. E.M.S.: None declared.

M.A.Z. was a member of the Clementia/Ipsen Data Safety Monitoring Board (DSMB) during the Palovarotene clinical trials and is currently on the Incyte DSMB. K.Z. is a clinical trial investigator for Incyte, Ipsen, and Regeneron. R.J.P. is a clinical trial investigator for Ashibio, Incyte, Ipsen, and Regeneron, a member of the Medical Registry Advisory Board of the IFOPA, and a consultant for Incyte, Ipsen, and Regeneron.

RJP is a co-inventor for the use of Andecaliximab in conditions of heterotopic ossification. Targets and potential therapies for fibrodysplasia ossificans progressiva. Frederick S. Kaplan Mona Al Mukaddam Genevieve Baujat Alberto Hidalgo Bravo Matthew Brown Amanda Cali Tae-Joon Cho Corrie Crowe Carmen L. De Cunto Patricia L. R.

Delai Robert J. Diecidue, Thomas Jefferson UniversityFollow Elisabeth Marelise W Eekhoff Lisa Friedlander Clive S. Friedman Zvi Grunwald, Thomas Jefferson UniversityFollow Nobuhiko Haga Edward C. Hsiao Richard Keen Joseph A. Kitterman Charles Levy Vrisha Madhuri Rolf Morhart J. Coen Netelenbos Christiaan Scott Eileen M.

Shore Michael Zasloff Keqin Zhang Robert J. Pignolo This article is the author’s final published version in JBMR Plus, Volume 9, Issue 11, 2025, Article number ziaf150. The published version is available at https://doi.org/10.1093/jbmrpl/ziaf150. Copyright © The Author(s) 2025. Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare genetic condition characterized by congenital malformations of the great toes and progressive heterotopic ossification (HO) in specific anatomic patterns.

Medical Guidelines For Fop Published In Jbmrplus Ifopa

People Also Search

Medical Guidelines For FOP Published In JBMRPlus We’re Pleased To

The Brain & Performance Centre Becomes The First UHMS-Accredited Hyperbaric

Researchers Examined Adverse Non-medical Drivers Of Health, Including Issues With

The Submission Deadline Is October 31, 2025, At: Https://lnkd.in/eA4-RsHN AASLD

This Section Features Key Materials Published In Dental And Medical